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The propeptide sequences of the vitamin K–dependent clot-





mylcarboxylase, which catalyzes the carboxylation of gluta-




 terminus of the mature
protein. We describe a mutation in the propeptide of Factor
IX that results in warfarin sensitivity because of reduced af-
finity of the carboxylase for the Factor IX precursor. The









1% on warfarin, at a point where other vitamin
K–dependent factors were at 30–40% activity levels. Direct
sequence analysis of amplified genomic DNA from all eight




adenosine transition at nucleotide 6346 resulting in an




10 in the propep-
tide. To define the mechanism by which the mutation re-
sulted in warfarin sensitivity, we analyzed wild-type and
mutant recombinant peptides in an in vitro carboxylation
reaction. The peptides that were analyzed included the
































values of 638 and 726 for A-10T and A-10G respectively, a






 values, on the other
hand, showed a 33-fold difference between wild-type and









M, respectively, for A-10T and A-10G. Similar
kinetic experiments showed no substantial differences be-
tween wild-type and mutant peptides in kinetic parameters
of the carboxylase–peptide complexes for reduced vitamin





Thr mutation is a reduction in affinity of
the carboxylase for the mutant propeptide. These studies
delineate a novel mechanism for warfarin sensitivity. In ad-
dition, the data may also explain the observation that bone
Gla protein is more sensitive to warfarin than the coagula-
tion proteins. (
 




























Vitamin K–dependent proteins include coagulation Factors




 proteins C, S,
and Z, bone Gla protein, matrix Gla protein, and a newly dis-
covered cell growth regulation protein, Gas6 (1). The biosyn-
thesis of the vitamin K–dependent proteins involves a complex
series of posttranslational modifications. Among these, re-
moval of the signal peptide and propeptide, N- and O-linked
glycosylation, hydroxylation of an asparate and in some cases,
cleavage at internal basic residues are common features shared





unique posttranslational modification that is required for the


















, the carboxylase also requires vi-
tamin K hydroquinone as a cofactor in the reaction (2). During
carboxylation, vitamin K hydroquinone is converted into vita-
min K epoxide. Regeneration of vitamin K is dependent on the
enzyme vitamin K epoxide reductase, the key enzyme targeted
by warfarin (Fig. 1). Thus, anticoagulation by warfarin indi-
rectly inhibits carboxylase by blocking the regeneration of vi-
tamin K hydroquinone.





propeptide sequence of the vitamin K–dependent protein. Jor-
gensen et al. showed that the propeptide sequence, which is
found in the precursors of the vitamin K–dependent proteins,
is essential for the carboxylation of recombinant human Factor
IX in Chinese hamster ovary cells (3), and Knobloch and Sut-
tie demonstrated that an amino-terminal attached propeptide











in vitro (4). Even though extensive conservation of sequence is
not seen in the propeptide sequences of the vitamin K–depen-









10, have been proven critical for carboxylation (Fig. 2
and reference 5). We report here an unusual mechanism of





10 of the propeptide of human Factor IX. Because
the patient was perfectly normal on coagulation screening tests
until challenged with warfarin, we studied the biochemical
mechanism of this defect. The system we chose is a well-estab-
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-carboxylation assay using substrates contain-
ing the mutant propeptide and Gla domain sequences of hu-
man Factor IX (6). Using Michaelis-Menten kinetics, we
demonstrated that the mutant peptide has a reduced affinity
for the carboxylase when compared to the wild-type peptide
substrate. This mutation is of interest from a scientific stand-
point because, among the vitamin K–dependent clotting fac-
tors, it is the first example of a naturally occurring mutation




-carboxylation. From a clinical
standpoint, the study of this mutation has allowed the elucida-






The patient is a 49-yr-old Caucasian male who was
referred for evaluation of bleeding complications that developed dur-
ing anticoagulation with warfarin. The patient’s history is significant
for a congenital bicuspid aortic valve with accompanying aortic steno-
sis and regurgitation. At the age of 49, he developed progressive left
ventricular hypertrophy and critical aortic stenosis, and underwent
placement of a St. Jude’s (tilting disc) valve. Preoperative coagulation
screening tests including the prothrombin time (PT) and the activated
partial thromboplastin time (aPTT) were within normal limits. The
patient’s immediate postoperative course was uncomplicated. He was
discharged on the fifth postoperative day, with prescribed medica-
tions, including warfarin, digoxin, furosemide, metoprolol, ferrous
sulfate, and oxycodone. Over the ensuing 2 mo, the patient was re-
peatedly admitted to the hospital for bleeding complications, includ-
ing a hemothorax, multiple episodes of hematuria, and episodes of
ecchymoses over the arms, legs, and trunk. Evaluation of coagulation
parameters repeatedly disclosed prolonged coagulation screens (e.g.,




 150 s), which corrected on mixing with normal
plasma. Factor assays obtained during one of these admissions









1%. When warfarin was stopped, screens returned to
normal, as did the F.IX activity level (148%). When warfarin was re-





stopping warfarin, the F.IX activity level rose to 120%.
The patient has a history of mild Charcot-Marie-Tooth disease,
manifest by muscular atrophy in the left lower extremity. The pa-
tient’s mother, his maternal grandfather, and two of his three children
also have Charcot-Marie-Tooth disease. The patient’s family history
was negative for bleeding diatheses. His physical examination was
positive for a thoracotomy scar on the chest, as well as moderately se-
vere muscle atrophy in the left lower extremity. Cardiac examination
was consistent with the presence of a mechanical valve in the aortic
position. Medications at the time of evaluation at this hospital in-
cluded metoprolol 50 mg bid and warfarin 2.5 mg for 3 d, then 5 mg
on the 4th d, then restart 2.5 mg. Laboratory evaluation on initial pre-









 24.0–39.0 s), F.VII activity
of 80%, F.IX activity of 16%, F.X activity of 43%, and protein C ac-

















, hemoglobin of 13.7 gm/dl, hematocrit of 41.2%, and a




. After informed consent, peripheral
blood was obtained for DNA analysis. The patient has remained free
of thrombotic and hemorrhagic complications on the warfarin regi-
men described.
 
Antigen and activity assays for coagulation proteins. 
 
PT and aPTT
were performed by a semiautomated method, using a Coag-A-Mate X2
instrument (Organon-Teknika, Research Triangle Park, NC). Rabbit
brain thromboplastin (Simplastin Excel; Organon Teknika) was used
as reagent for the PT assay, and rabbit brain phospholipid (Platelin)
was used as reagent for the aPTT. Activity assays for Factors VII, IX,
and X were performed on patient plasma diluted into factor-deficient
Figure 1. g-carboxylation of vi-
tamin K–dependent proteins. 
The g-glutamylcarboxylase re-
quires reduced vitamin K, CO2, 
and O2 as cofactors for the carbox-
ylation of vitamin K–dependent 
proteins. In the reaction, g-glu-
tamylcarboxylase catalyzes the ox-
idation of 1 mol of reduced vita-
min K to vitamin K epoxide for 
each mole of CO2 incorporated 
into the peptide.
Figure 2. Amino acid sequence alignment of the propeptides of the 
vitamin K–dependent proteins. Highly conserved residues are shaded 
in gray. These include, in addition to the basic residues at the COOH-
terminus, alanine at residue 210 and phenylalanine at residue 216. h, 
human; b, bovine; r, rat; m, mouse; S, protein S; C, protein C; BG, 
bone Gla protein; MG, bone matrix Gla protein; GAS6, growth ar-
rest–specific protein.
 




plasma using either a PT- (F.VII) or aPTT-based (F.IX and F.X) as-
say. Protein C activity was determined using a commercially available
chromogenic assay (American Bioproducts, Parsippany, NJ). F.IX
antigen level was determined by an ELISA in which a commercially
available rabbit anti–human F.IX polyclonal antibody (Dako Corp.,
Carpinteria, CA) was used as the capture antibody, and a polyclonal
goat anti–human F.IX antibody coupled to horseradish peroxidase





Genomic DNA was purified from peripheral
blood according to the method of Bell et al. (7). Genomic DNA was













M amplification primers, and 200 mM dNTPs in a





gelatin. Amplification primers previously described (9) were derived
from intron sequences such that all exons and intron–exon junctions










 polymerase (Perkin Elmer Corp., Norwalk, CT), the reaction



















C (denaturation). PCR reaction mixtures were subjected to 1%
agarose gel electrophoresis in Tris-borate-EDTA buffer at 95 V.
DNA bands were visualized by ethidium bromide staining and ex-
cised. DNA was purified from the isolated agarose fragments and re-




l of distilled, deionized water for dideoxy sequence










l of 10% Nonidet P-40 (Sigma Immunochemicals, St. Louis,









l of water were added to the reaction, and
dideoxy sequencing reactions were carried out with Sequenase ac-
cording to the manufacturer’s instructions. Termination reactions
were separated on a 6% denaturing polyacrylamide gel at 75 W, and





cDNAs encoding the substitution of





10 in the human F.IX propeptide were produced by overlap-




 polymerase (New England Biolabs, Beverly,
MA; reference 10). The threonine substitution is based on the muta-
tion in the patient; the glycine substitution was produced to replicate
the homologous residue in bone Gla protein (11, 12). The template
used was the vector pMa1422, which is derived from pMc292 (6) and
directs the expression of a fusion protein of phage T7 gene 10 and a









the mature protein. In the first round of PCR, a 394-bp fragment con-




 end and a 189-bp fragment containing




 end were amplified. The second round of PCR
used a mixture of the first two products (annealed at the site of over-
lap that includes the desired mutation) as template and the original
flanking oligomers. A 583-bp fragment was generated which was di-
gested at internal NcoI and BamHI sites and subcloned into the
pMa1422 vector digested with the same enzymes. After subcloning,
the mutations were confirmed by DNA sequence analysis.
 
Expression, purification, and characterization of wild-type and
mutant peptides. 
 
T7 gene 10 fusion proteins were synthesized as pre-




 (6). Inclusion bodies were iso-
lated from a 4-liter culture. After cyanogen bromide cleavage, the
dried peptides were resuspended in 50 ml of 8 M guanidine-HCl. The
peptides were sulfonated by the addition of 0.15 gm sodium tetra-
thionate and 0.3 gm sodium sulfite, pH was adjusted to 9.0 with am-
monium hydroxide, and the reaction was incubated at room tempera-
ture for 16 h. The sulfonated peptides were then dialyzed against three
changes of 25 mM MOPS pH 8.0, 10 mM NaCl to precipitate the gene
10 fragments while the target peptides remained in solution. The gene




 for 15 min.
The supernatant was loaded on a DEAE-Sepharose CL-6B (5 ml)
column, and the target peptide was eluted with 250 mM NaCl. Sul-
fonation was reversed by incubating the eluted peptides at room tem-
perature for 3 h with 100 mM DTT. The peptides were further puri-
fied by reverse-phase HPLC using a widebore C-18 column (300 Å
pore size: Rainin Instrument Co. Inc., Woburn, MA). Peptides were
eluted using a linear gradient (1 ml/min) of 0% buffer A (0.1% triflu-
oroacetic acid) to 100% buffer B (90% acetonitrile/0.1% trifluorace-
tic acid) over 10 ml. The peptides were dried and resuspended in 10
mM ammonium hydroxide.
 
Confirmation of peptide molecular weight by electrospray ionization
mass spectroscopy. 
 
The molecular mass of each peptide was deter-
mined using a VG Quattro BQ triple quadropole mass spectrometer
(Fisons Instruments, Inc., Danvers, MA) equipped with a pneumati-
cally assisted electrostatic ion source operating at atmospheric pressure.
Samples were reconstituted in 50% aqueous acetonitrile containing
formic acid (1% vol/vol), and were introduced by loop injection into





spectra were acquired in the multichannel analyzer (MCA) mode
from mass-to-charge (m/e) 700–1400 with a scan time of 10 s. The










16951.48) with a resolution corresponding to a peak width half
height of 1.0 D for m/e 893. The mass spectra were transformed to a
molecular mass scale using software supplied by the manufacturer.
 
Peptide kinetics assay. 
 
In this assay, washed bovine liver micro-


















. Reactions are initiated by the addition of the peptide substrates,









 into peptides. Microsomes and vitamin K hydro-
quinone were prepared as previously described (6). All kinetic assays




l using 1 mg of microsomal pro-
teins in 25 mM Mops, pH 7.4, 0.5 M NaCl, 0.4%, 3-[(3-cholamidopro-





















54 mCi/mmol), and the appropriate amount of the peptide substrate.
For kinetics assays, the microsomes were presolubilized with 1%
CHAPS on ice for 10 min with 125 mM Mops, pH 7.4, and 1 M NaCl.








 were then added for a




C. The reaction was initiated by adding the









M). The final concentrations of the
peptides used in the kinetic studies were determined by amino acid
analysis using aminobutyric acid as an internal standard. The reaction




C for 10 min, at which point the reaction




l 1 N NaOH. The samples were


















mined by scintillation counting. In our experience, human wild-type
substrates are efficiently carboxylated by bovine microsomes, so in-
terspecies variations do not impede the assay.
 
Vitamin K kinetics assay. 
 
The reaction conditions were identical
to those used in the peptide kinetics experiments, except that re-










wild-type peptide and 10 
 
mM for the mutant peptides. Additional ex-
periments were performed at peptide concentrations of approxi-
mately five times the Km (1 and 50 mM, respectively).
Data analysis. Kinetic parameters were determined using non-
linear least squares analysis and fitting the data to the Michaelis-
Menten equation. All reported kinetic values are averages of at least
two independent assays.
Results
Warfarin sensitivity results from a profound drop in F.IX activ-
ity levels in response to warfarin therapy. The patient’s F.IX
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activity level is within normal limits (148%, 120%) when the
patient is not ingesting warfarin. This is entirely consistent
with the absence of any bleeding history before the initiation
of warfarin therapy. During the first 4 mo of therapy with war-
farin, it was repeatedly documented that usual doses of the
drug, sufficient to prolong the PT into the therapeutic range,
were associated with a dramatic reduction in the patient’s F.IX
activity level, to , 1%, at a time when the other vitamin
K–dependent clotting factors were only moderately reduced.
When referred for evaluation, the patient was on a lower dose
of warfarin (not sufficient to prolong the PT), but the sensitiv-
ity of the F.IX level to warfarin was still evident, with a F.IX
activity level of 16% at a time when F.VII and F.X levels were
80 and 43%, respectively. The F.IX antigen level by ELISA
was 30%.
Mutation analysis discloses a missense mutation in exon 2 of
the F.IX gene. Direct sequence analysis of amplified genomic
DNA from all eight exons and from the exon–intron junctions
of the F.IX gene demonstrated a single difference from the
wild-type sequence, a guanosine→adenosine (G→A) transi-
tion at nucleotide 6346 (numbering according to Yoshitake et al.
(13)) in exon 2 (Fig. 3). The mutation was confirmed by se-
quence analysis of the opposite strand and by sequence analy-
sis of three independent PCR amplification products. This sin-
gle nucleotide change results in the substitution of threonine
for alanine at residue 210 in the propeptide.
The mutant propeptide has a reduced affinity for the carbox-
ylase. Previous work has shown that a 59–amino acid peptide
spanning residues 218 to 141 of the F.IX protein is an excel-
lent substrate for g-glutamylcarboxylase, with an apparent Km
in the micromolar range (6). Peptides that were analyzed in
this study included the wild-type sequence, the A-10T se-
quence, and an A-10G sequence, a substitution based on the
sequence in bone matrix Gla protein (11, 12). The molecular
weights of the peptides were confirmed by electrospray ioniza-
tion mass spectroscopy. Experimentally determined molecular
weights (7052.2260.61, 7081.6160.28, and 7038.4560.41 for
wild-type, A-10T, and A-10G, respectively) were in close
agreement with predicted values for these peptides (7052,
7082, and 7038). The Km was determined for the wild-type sub-
Figure 3. Nucleotide sequence of exon 2 
of amplified genomic DNA from normal 
control and from variant F.IX. A G→A 
transition at the first nucleotide of codon 
210 (nucleotide 6346 [13]) changes ala-
nine to threonine in the propeptide of 
F.IX.
Figure 4. Kinetic analysis of the g-carboxylation of F.IX peptides. 
The affinity of the carboxylase complex (g-glutamylcarboxylase and 
reduced vitamin K) for a peptide containing the normal propeptide 
and Gla domain sequence of F.IX and two variant peptides contain-
ing the propeptide sequences found in the patient (A-10T) and in 
bone Gla protein (A-10G) are determined by the addition of varying 
concentrations of the peptides. The wild-type peptide has a higher af-
finity for g-glutamylcarboxylase (Km 5 0.2960.02 mM) than A-10T 
(Km 5 10.961.2 mM) and A-10G (Km 5 9.561.7 mM). Maximal ve-
locities (Vmax) for the variant peptides are approximately equivalent 
(638632 cpm·min21 for A-10T, and 726656 cpm·min21 for A-10G), 
and are only twofold higher than Vmax for the wild-type peptide 
(343621 cpm·min21). Vitamin K concentration was 222 mM for all 
three reactions.
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strate (0.29 mM) and for the variants (10.90 and 9.50 mM, re-
spectively, for A-10T and A-10G) (Fig. 4 and Table I). The
Vmax values are roughly equivalent; Vmax of the variant sub-
strates is only twofold higher than that for the wild-type. Thus,
the major difference between the variant and wild-type pep-
tides as substrates for the g-glutamylcarboxylase is in the Km,
indicating that the mutant peptides have a more than 30-fold
lower affinity for the carboxylase.
The mutation in the propeptide does not alter the affinity of
the enzyme–peptide complex for reduced vitamin K. In the con-
version of peptide substrates to carboxylated products by
g-glutamylcarboxylase, reduced vitamin K is converted to vita-
min K 2, 3-epoxide as part of the reaction. In this sense, vita-
min K can be regarded as the substrate of the carboxylase, in
which case the enzyme could be called vitamin K epoxidase.
Previous work (14) has demonstrated that there is 1:1 stoichi-
ometry between incorporation of CO2 into a peptide substrate
and oxidation of vitamin K. Therefore, vitamin K kinetics can
be monitored by following CO2 incorporation into the peptide
substrates. The reactions are carried out in a fashion similar to
those described above, except that the peptides are added to
the preincubation, and reactions are initiated by adding re-
duced vitamin K. The results shown in Fig. 5 and Table II were
carried out at peptide concentrations near the Km (0.3 mM for
wild-type, 10 mM for mutant peptides), and demonstrate only
a modest difference in Vmax between the complex formed with
the wild-type peptide and those formed with the variant pep-
tides. In particular, the Vmax for wild-type and A-10T are simi-
lar, and that for A-10G is z 1.6 times that of wild-type. There
is a twofold increase in Km for the variant peptides compared
to wild-type. These Km values were confirmed in additional ex-
periments carried out at higher peptide concentrations (1 mM
for wild-type, 50 mM for mutant peptides). Thus, both en-
zyme–peptide complexes containing variant peptides have
lower affinities for vitamin K than the complex containing the
wild-type peptide, but the difference is not marked.
Discussion
In this report, we describe the first naturally occurring muta-
tion in a vitamin K–dependent clotting factor that directly af-
fects carboxylation by the g-glutamylcarboxylase; the object of
the studies in the report is to determine how the mutation af-
fects carboxylation and leads to a syndrome of warfarin sensi-
tivity.
With no antecedent history of a bleeding diathesis, this pa-
tient was repeatedly hospitalized with bleeding complications
on warfarin at a time when the PT was in the therapeutic
range. Preoperative coagulation screens had been within nor-
mal limits, but during warfarin treatment, the patient’s F.IX
activity fell to , 1% while the F.VII level was 42%. Off war-
farin, the F.IX level rose to . 100% (documented on more
than one occasion), ruling out undiagnosed hemophilia B as
the cause of the patient’s difficulties. Direct sequencing of am-
plified genomic DNA from the patient’s F.IX gene disclosed a
single-point mutation that results in the substitution of threo-
nine for alanine at position 210 in the pre-pro leader se-
quence. This mutation falls within the propeptide sequence,
which has been shown to be the essential recognition element
for carboxylation (3). The most highly conserved residues
within the propeptide (Fig. 2) are a phenylalanine at position
216 and an alanine at position 210. An alanine is found at po-
sition 210 in all the known vitamin K–dependent proteins ex-
cept bone Gla protein, where a glycine is present at 210.
There are no previous reports of naturally occurring muta-
tions at position 210 (15), but the importance of this residue
Table I. Kinetics of IX218 to 141 Peptides in Microsomes 
Peptide Kinetics
Peptide Km Error* Vmax Error Vmax/Km
mM cpm/min cpm/min·mM
Wildtype 0.29 0.02 343 21 1180
A-10T 10.9 1.20 638 32 58.5
A-10G 9.50 1.70 726 56 76.4
*For Tables I and II, each determination was done at least twice; error
is defined as standard error of the mean for averaged values.
Figure 5. Kinetic analysis of reduced vitamin K in g-carboxylation of 
F.IX peptides. The affinity of the carboxylase complex (g-glutamyl-
carboxylase and F.IX peptides) for vitamin K is determined by the 
addition of varying concentrations of reduced vitamin K to initiate 
the carboxylation reaction. The Km of the complex containing the 
wild-type peptide is 4.260.24 mM; the complexes containing the vari-
ant peptides have only a twofold lower affinity for vitamin K (Km 5 
9.361.5 for the complex containing the A-10T peptide and 8.660.20 
for the A-10G peptide). The Vmax for each complex is similar 
(383621, 454615, 612636 cpm·min21 for wild-type, A-10T, and 
A-10G, respectively).
Table II. Kinetics of IX 218 to 141 Peptides in Microsomes 
Vitamin K Kinetics
Peptide Km Error Vmax* Error Vmax/Km
mM cpm/min cpm/min·mM
Wildtype 4.2 0.24 383 21 91.2
A-10T 9.3 1.50 454 15 48.8
A-10G 8.6 0.20 612 36 71.2
*Maximal rate at 0.3 mM wild-type peptide and 10 mM A-10T or A-10G.
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has been demonstrated by Rabiet et al., who showed that sub-
stitution of glutamic acid for alanine (a nonconservative
change) in a recombinant F.IX variant resulted in a species
that was poorly carboxylated in CHO cells, with , 2 mol of
Gla/mol protein, compared to an expected content of 12 mol
Gla/mol protein (5). Cheung et al. have also examined the af-
finity of chemically synthesized F.X propeptides for the car-
boxylase by determining their ability to stimulate carboxyla-
tion of the pentapeptide substrate FLEEL in vitro. In these
experiments, the substitution of glutamic acid or valine for ala-
nine 210 resulted in no detectable binding to carboxylase (16).
To understand the defect reported here at the molecular
level, we used a well-characterized system for constructing
peptides and assaying their kinetic properties toward the car-
boxylase (6). The peptides, synthesized in a bacterial expres-
sion system, consist of the wild-type or mutant propeptide co-
valently linked to the Gla domain of F.IX. Studies by a
number of groups (4, 14, 17, 18) have shown that attaching the
propeptide to the substrate lowers the apparent Km of reduced
vitamin K for the carboxylase. Thus, for example, when the
pentapeptide FLEEL is the substrate, the apparent Km for re-
duced vitamin K is z 100 mM, but a 59–amino acid sequence
spanning the region from 218 to 141 of the human F.IX pro-
tein has a Km app 100-fold lower (z 1 mM; reference 18).
Based on these data, we initially hypothesized that a mutation in
the propeptide sequence would result in a higher apparent Km of
the peptide–enzyme complex for reduced vitamin K. Since
warfarin treatment results in a marked decrease in the levels of
reduced vitamin K, it is a reasonable prediction that the muta-
tion would thus result in markedly decreased levels of F.IX ac-
tivity in the presence of warfarin. This hypothesis, however, is
not supported by the in vitro kinetic studies, which show that
the major difference between wild-type and variant peptides is
the 30-fold increase in the apparent Km of the variant peptide
to the carboxylase compared to the wild-type peptide. The Km
of the enzyme–variant peptide complex for reduced vitamin K
was only approximately twofold higher than that of the en-
zyme–wild-type complex, so that the mutation does not result
in markedly altered affinity of the complex for vitamin K. In-
stead the data show that a propeptide containing threonine at
position 210 is a poor substrate for carboxylase compared to
one with alanine at position 210. Although one must always
be cautious in extrapolating results from in vitro studies to the
in vivo setting, it seems likely that the low affinity of the car-
boxylase for the mutant propeptide is the difference that ac-
counts for the dramatic reduction in F.IX levels on warfarin.
This observation in turn, however, raises the question of
why the patient has normal levels of F.IX in the absence of
warfarin. We propose the following explanation. As originally
pointed out by Segel (19), the Km establishes an approximate
value for the concentration of a substrate in vivo. This allows
for maximal responsiveness of the reaction rate to changes in
substrate concentration. Thus, in the absence of warfarin, the
concentration of the mutant F.IX precursor may be 30-fold
higher than that of the wild-type substrate. This accumulation
of the precursor allows for the synthesis of normal levels of
fully processed F.IX despite its reduced affinity for the carbox-
ylase. In the presence of warfarin, however, the precursors of
all the vitamin K–dependent proteins begin to accumulate
(20). When all of the substrates are present at increased con-
centrations, the reduced affinity of the carboxylase for the mu-
tant F.IX substrate results in a marked decrease in carboxyla-
tion of the mutant F.IX. This interpretation can be expressed
mathematically by an equation that gives relative reaction ve-
locities for two competing substrates (21):
vmutant F.IX/vwt 5 (kcat/Km)mutant[mutant F.IX]/(kcat/Km)wt[wt]
In the absence of warfarin, the intracellular concentrations
of both substrates are approximately equal to their respective
Km values, and the two terms cancel out so that the relative
rates are only dependent on the relative kcat values. Since kcat is
proportional to Vmax, the F.IX levels are similar and within the
normal range. In the presence of warfarin, however, the concen-
trations of all substrates rise 10–20-fold (20); the concentration of
F.IX, already near maximum, cannot rise further, and the car-
boxylation of the precursors of the other vitamin K–depen-
dent factors outcompetes the mutant F.IX precursors.
The low affinity of the carboxylase for the mutant propeptide
may contribute to the low levels of active F.IX by another
mechanism. Morris et al. (22) have demonstrated that the
g-glutamylcarboxylase is a processive enzyme such that multiple
carboxylations occur in a single enzyme–substrate association.
Warfarin inhibits the regeneration of vitamin K hydroquinone
and thus reduces its availability for the reaction; this slows the
process of carboxylation. Therefore, if the amount of time
the substrate remains bound to the carboxylase is reduced by
the lower affinity of the mutant propeptide, premature dissocia-
tion of the enzyme–substrate complex may result in incomplete
carboxylation. This effect may account in part for the pro-
nounced reduction in F.IX activity compared to the other vita-
min K–dependent proteins, and may also explain the discrep-
ancy between the F.IX antigen and activity levels in this patient
(30% antigen, 16% activity when both were measured simulta-
neously). It should be noted, however, that such a discrepancy
is routinely seen in patients on warfarin (23) and thus can be
accounted for without invoking the presence of the propeptide
mutation.
It is of note that the A-10G substitution, based on the resi-
due found in bone Gla protein, also results in a 30-fold re-
duced affinity for the carboxylase and virtually no change in
affinity for reduced vitamin K. This finding was somewhat sur-
prising, since the change is a conservative one. The weight of
the evidence begins to suggest that alanine is uniquely re-
quired at position 210 for efficient binding to the carboxylase.
Fairly conservative changes such as Ala→Gly or Thr (this
work) or Val (16), as well as less conservative changes such as
Glu or Asp (5, 16), appear to have a very significant influence
on binding affinity. The kinetic studies with the A-10G substi-
tution also provide an explanation for the observation made a
number of years ago that bone Gla protein is more sensitive to
warfarin than to coagulation proteins. Price and Kaneda docu-
mented in a rat model of warfarin treatment that bone Gla
protein is reduced to 5% of normal at a point when the activity
of coagulation proteins is unaffected (12). These investigators
proposed that this difference might reflect a difference in vita-
min K metabolism in hepatocytes vs. osteoblasts. Our data sug-
gest that the difference is caused by a reduced affinity of the
bone Gla precursor for the carboxylase in a manner analogous
to the Ala→Thr mutation in F.IX. This finding is important,
since it challenges the longstanding but poorly documented as-
sumption that all naturally occurring peptide substrates have
similar affinities for the carboxylase. Additional support for
the notion that affinities differ among substrates is provided in
a recent preliminary report by Gillis et al., in which the Km val-
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ues of the Gas6 and protein S propeptides for the carboxylase
were reported to be z 100 and 400-fold higher, respectively,
than the Km for a prothrombin substrate (24).
This naturally occurring mutation is of considerable interest
because it represents a novel mechanism of warfarin sensitivity.
Other causes of warfarin sensitivity, including liver disease, vita-
min K deficiency, drug interactions, or hyper-metabolic states
are associated with prolongation of the PT, and were excluded in
this patient. We have recently become aware of another patient
with a similar presentation, i.e., normal F.IX levels off warfarin
and marked reduction of F.IX activity levels on warfarin, at a
time when activity levels of other vitamin K–dependent factors
are more modestly reduced (J.A. Humphries, personal commu-
nication). This patient also has a mutation in the propeptide of
F.IX at a residue (position 29) adjacent to the one described
in the current report (Chu, K., and K.A. High, unpublished ob-
servation). Thus the mechanism of warfarin sensitivity that we
describe here may account for other unexplained cases of hy-
perresponsiveness to the drug. It should be noted that a clue to
the underlying pathophysiology in these cases is the markedly
prolonged aPTT in the face of a therapeutic PT. Propeptide
mutations in other vitamin K–dependent clotting factors
would be less likely to cause warfarin sensitivity, since these
genes are located on autosomes, and it would be necessary to
have the mutation present on both alleles to observe the effect.
Similarly, the syndrome of warfarin sensitivity caused by F.IX
propeptide mutations should be observed primarily in males.
It is interesting that this mutation is phenotypically silent
except when the patient is undergoing therapy with warfarin.
This is reminiscent of the data reported for certain mice created
by “knockout” technology, where the effects of gene inactivation
are not apparent unless the organism is stressed (25). These
examples make it clear that it may be difficult or impossible to
judge the role of a specific protein (or of a particular residue
within a protein) in homeostasis in the undisturbed state.
In summary, we have carried out a series of in vitro carbox-
ylation studies on peptide substrates designed to mimic a natu-
rally occurring propeptide mutation and a change found in
bone Gla protein. These studies document the first example of
a naturally occurring mutation in a vitamin K–dependent pro-
tein that has a direct effect on the efficiency of carboxylation.
The studies elucidate a novel mechanism of warfarin sensitiv-
ity, and also suggest that the longstanding assumption that all
the propeptides have similar affinity for the carboxylase may
be incorrect.
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